Update: chronic myelogenous leukemia clinical practice guidelines.

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Oncology are typically updated annually.
• A recent guideline update for chronic myelogenous leukemia (CML) occurred sooner than usual.
• This update incorporated the tyrosine kinase inhibitor STI-571, also known as imatinib mesylate, following its U.S. Food and Drug Administration (FDA) approval.

Purpose of the Study:

• To reflect the significant impact of imatinib mesylate on CML treatment.
• To address unresolved clinical questions regarding the optimal use of imatinib in CML management.
• To guide clinical decision-making for CML patients concerning imatinib therapy versus early transplant.

Main Methods:

• Review and update of existing NCCN Clinical Practice Guidelines for CML.
• Inclusion of newly FDA-approved imatinib mesylate into treatment recommendations.
• Panel discussion to address outstanding clinical questions.

Main Results:

• The NCCN guidelines now include imatinib mesylate as a treatment option for CML.
• The introduction of imatinib has fundamentally changed CML treatment paradigms.
• Significant clinical questions persist regarding long-term cure rates with imatinib and the role of early transplantation.

Conclusions:

• Imatinib mesylate represents a major advancement in the treatment of chronic myelogenous leukemia.
• Further research and clinical evaluation are necessary to fully define the long-term efficacy and optimal sequencing of imatinib therapy.
• Determining which CML patients can be cured with imatinib versus those who still benefit from early stem cell transplantation remains a critical area of inquiry.